GE Healthcare said the final module of its premarket approval application for the GE Breast Tomosynthesis system has been forwarded to the FDA. The technology, which serves as an add-on option for the company's Senographe Essential device, delivers 3D digital images of the breast to aid in the detection of breast cancer.

Related Summaries